Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Western Union Co (WU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Western Union Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Western Union Co trades at $7.85 (market cap $2.45B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 16.3× Western Union Co's market cap, and Western Union Co pays a 11.99% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WU | |
|---|---|---|
Market Cap | $39.89B | $2.45B |
Sector | Health | Technology |
52-Week High | $491.22 | $10.28 |
52-Week Low | $278.09 | $7.04 |
Enterprise Value | $38.15B | $2.14B |
Dividend Yield | — | 11.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Western Union (WU) trades at $7.84, up 0.26% on the day, with a bearish technical signal despite recent positive earnings beats. The stock shows strong profitability with a 10.88% net margin and attractive valuation ratios, including a P/E of 5.76. Recent news highlights strategic partnerships, such as the integration with Total Wireless, expanding its digital payment reach.
The outlook is mixed; low valuations and dividend yield present opportunity, but declining revenue, a recent earnings miss, and high debt pose risks. Analyst sentiment is cautious with only 12.5% buy ratings. Investors should weigh the value proposition against execution challenges in a competitive money transfer landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
